The Calmer Co International Limited (CCO) Earnings Call Transcript & Summary

August 7, 2026

Australian Securities Exchange AU Consumer Staples Personal Care Products earnings 57 min

Earnings Call Speaker Segments

Zane Yoshida

executive
#1

Thank you for joining us for the first time on the webinar. Once again, welcome to our Q4 FY '26 webinar. I'm Zane Yoshida, Founder and CEO of The Calmer Co; and Matthew Kowal, our Chief Commercial Officer, is also here with me to cover any topics today. If we can, Matt, let's move to the second slide. We'll be talking about a range of topics, starting with the strategic pillars in the business, which we speak to consistently — our regional sourcing, manufacturing and innovation followed by direct-to-consumer, including Amazon, a scalable, profitable retail followed by wholesale. I'll go through some of the quarterly highlights, discuss revenue performance, and hand over to Matt at that stage for him to update on the revenue for the quarter, where that's come from, where the shift has been followed by cash costs and funding and regulatory and outlook for FY '27. Let's move to the next slide. Thank you, Matt. Apologies again for the technical issues earlier on. So I guess from a strategic pillar perspective, the objective for The Calmer Co is to continue to expand its sourcing capability outside of Fiji. We've been very comfortable building a pipeline of supply with direct relationships that we've had with farmers across Fiji.

Zane Yoshida

executive
#2

We've built relationships in Vanuatu and Papua New Guinea too. We're in discussions with exporters from a few additional places and hope to wrap something up there. Solomon Islands has proven somewhat difficult, since we don't yet have commercial volumes for exports from the Solomons in any meaningful way. So our real focus is on supply chains beyond Fiji, making sourcing from Vanuatu and Papua New Guinea stronger. And I'm glad to report that only yesterday we announced a comprehensive supply agreement aimed at bolstering this strategic pillar, especially with PNG and Vanuatu, to source <<inaudible>>. Another point is testing capability and reinforcing quality assurance. A central focus for the business and a key value proposition and differentiator, really, is traceability and transparency. And since we send our trucks to remote locations and bring Cava back to the factory, completing the associated forms all the way through to finishing lot numbers, which create batch numbers, and being able to trace that right back to an individual pharma or a region or province, that's a big advantage for us alongside our ongoing quality control. Beyond that, we'll touch on testing.

Zane Yoshida

executive
#3

So right now, if we take Tescava as an example, we rely on a technique known as high-performance liquid promotography, along with gas chromatograph free and mass spectrometry. These instruments are extremely useful. Whenever you examine kava through a scientific approach, what you generally measure is the total kavalectone concentration present in the raw material, but you also examine what are known as chemotype profiles. Beyond chemotype profiles, you also check other kavalectones, including flavor carven. Considering certain historical worries in Western markets, monitoring flavor carven is a crucial element of our quality control for the raw materials we process and incorporate into finished products or sell through our wholesale channel, whether in a water extract or a CO2 extract format. So we're pleased to report that we're proceeding with commissioning our GCMS equipment, and our competitive edge there is that at present, when exporters want carven testing done in Fiji, it's either performed at the University of the South Pacific or at Douglas Pharmaceuticals. Those are the only 2 accredited labs carrying out Kava testing. The frustration, I suppose, for many exporters is how long it takes to get those results back.

Zane Yoshida

executive
#4

Typically, turnaround runs 5 to 7 weeks from the time samples are submitted, and the cost per individual sample ranges from $750 to $950 as well. So the advantage we gain from commissioning our GCMS equipment is this: we partner with a lab located in the United States, based out of Utah. We handle the sample preparation of raw material, and the subsequent analysis plus interpretation of results takes place at an accredited laboratory in Utah, with turnaround times usually 24 to 48 hours. That's a huge advantage for a company like ours, especially as we move beyond Fiji to make sure the quality and integrity of the material is compliant and usable with our finished products. With the supply agreement we've just announced as well, to expand into PNG as well as Vanuatu, Noble Kava materials. We also have an agreement ensuring that the materials this company is bringing into the country are quality assured without testing through GCMS as well. So it's a win-win situation, with much condensed lead times for analysis and interpretation of results, particularly as we look to develop formulas for consistency with potency and chemotype formats for different strategic pillars that I'll touch on in the business.

Zane Yoshida

executive
#5

The second one is direct-to-consumer, and that covers Amazon U.S.A. Looking back over the quarter from June 30, we were still running direct-to-consumer through a salesforce platform. We've decided to switch back to a shopper platform and to have our internal team handle this portion of the business rather than relying on an outside resource or agency for direct-to-consumer management. For us, Amazon remains a major contributor to revenue generation quarter to quarter. That side of the business continues to be run by Andy Burger — for anyone unfamiliar with Andy, he had 20 years at Amazon before moving on to other e-commerce companies, and over roughly the last 12 months he has helped us grow with Amazon U.S.A. So e-commerce is growing, producing 30% of revenue in the quarter. Amazon U.S.A. accounted for $457,000 of that, while we showed a savings in marketing spend tied to direct-to-consumer — in particular, down 31% quarter-on-quarter. The other strategic pillar we discuss is profitable, scalable retail. And naturally, we have partnerships in Australia with Coles and Woolworths. We continue to hold the #1 and #3 positions in coal supermarkets across Australia with our unflavored Kava formats like this one — we offer a 150-gram pack and a 50-gram pack at Coles nationwide.

Zane Yoshida

executive
#6

In a similar vein, with Woolworths we offer a 50-gram pack throughout its supermarkets across Australia. We issued an announcement about expanding that range with Coles specifically, and Matt will address it in the slides coming up. What excites us, though, is this: over the past 4 years, ever since the Kava commercial pilot trial was announced, we've climbed to the number 1 and #3 spots, respectively, in the stress and vitamin category across all the core supermarkets. Now, we know Kava definitely works. We know Kava has a lengthy track record in Western markets as a prescription medicine for addressing anxiety together with pharmaceutical medicines like Zynex, Valium and Prozacs. So certainly, when you look at the connection among stress, anxiety and sleep, that remains a major driver with Australian consumers, who are warming to Kava and who use it repeatedly to help with these elements, plus to support a better night's sleep. Our other major driver, as we've said before, is Gen Zs. Gen Zs are a fascinating demographic, in that an estimated 30% of them no longer drink alcohol and are seeking safer, healthier alternatives to alcohol.

Zane Yoshida

executive
#7

So in that sense, we have definitely observed rising demand for Cava—still niche, naturally, but Gen Zs are adopting Kava products and Kava ingredients more and more. The thrilling part, naturally, is that through a TGA pathway regulated as a complementary medicine, we will be first to market in Australia. And I'll give you a quick demo of how these look. They taste wonderful, certainly. It's a pineapple coconut flavor, and with the convenience of sachet or stick pack formats, we're genuinely excited to see how the product performs. We're eyeing a launch in Coles Supermarkets in Q2 FY '27. But having consumed traditional covers and now tasted this through the R&D process, I believe they should do really well, Matt. So retail revenue rose 24% quarter-on-quarter. For Q4 FY '26, it's our largest channel. And naturally, the new FZZR formats we're looking to launch in Q2 FY '27 have us buoyed. Our wholesale bulk ingredient channel is the fourth strategic pillar. And with existing relationships we have with Network Nutrition, IMCD on water extract formats that we've been selling through this channel for some years now, we continue to make very strong progress.

Zane Yoshida

executive
#8

But with the push into higher-potency formats, we've also standardized 30% Kavolactone formats. In the past, we only had a 10% potency and an 8.5% potency. Now this extends to a 65% Kavolactone paste and a 30% Kavalectone powder, which we're selling through direct relationships and also proposing to sell through distribution relationships that we're currently working on within the company. And again, Matt will speak to that and how it's progressing in the slides coming up. So on a wholesale basis for the quarter, we hit $305,000 in wholesale revenue for the quarter, which added 18% to total group revenue, and 76% of that came from the U.S.A. Let's go to the next slide, please, Matt. So the key highlights for the quarter: while we may have been marginally down in the wholesale channel, particularly given how lumpy sales can be while we keep building this pipeline of relationships for our extract formats, we finished the quarter at $1.72 million in revenue. Retail growth rose 24%. And Australia revenue quarter-on-quarter was up 22% again. Cash receipts grew by 15%. And if you think about how this rebalances the quarter in Q3 FY '26, we reported that the bulk of our revenue was generated in the United States.

Zane Yoshida

executive
#9

I believe that figure was around 56%. The biggest piece of that came from wholesale for the period, or it was split fairly evenly among all our revenue-generating pillars — roughly 33% from retail, 33% from direct-to-consumer, which includes Amazon, and about 33% from wholesale. So we're still quite encouraged by the positive momentum we've seen in our wholesale channel more recently, over the past couple of weeks. We've managed to formalize a heads of agreement with Timing Agro Processing out of Fiji, and some background there: Timing has been operating in manufacturing within the ginger industry for 40 years now in Fiji. He is certainly the biggest processor and exporter of ginger and turmeric formats. What the heads of agreement means is that, beyond Kava extracts, our growth processing is looking to invest in supercritical CO2 equipment manufacturing with a brand-new facility outside of Navu, Fiji. And he's looking to move into ginger and turmeric extract formats using CO2 extraction as well. So the relationship is very complementary in the sense that we've been able to move from R&D through to commercialization with our CO2 extract Kava format — in particular, we have a take-or-pay contract that we announced with a functional beverage company earlier this year to the tune of AUD 2 million in revenue over the 24-month period.

Zane Yoshida

executive
#10

And as a complement to that, I suppose, with the relationships we already have in place with companies such as IMCD, which are already selling ginger and tumor extract formats, we see a very good plug-and-fit there in that sense. Beyond that, we're aiming to streamline operations coming out of Fiji. And given how successful Kelvin's efforts have been in supporting other U.S.A. companies with ginger production, we're looking to put Kelvin in charge of production for Fiji Kava, Takumi, and authentic Kava branded products that we presently make out of F — we will, however, still keep control over the supply chain, and we continue to reinforce our supply of raw materials where Kava is concerned to make sure we have the volumes, the sustainable volumes, and the quality entering that facility for conversion into finished goods. So I think that leaves us very strongly positioned in that sense to really speed up the wholesale interest around the table and get to realizing very strong, meaningful revenue in the quarters ahead. Thank you, Matt. We'll move on to the next slide.

Matthew Kowal

executive
#11

Yeah, I'll pick it up from here. So, you know, when I look at how the last quarter played out and build a bit on what Zane said a moment ago, retail in Australia had a genuinely strong quarter. That came partly from some work around category events and a price increase, but also from real growth in interest across the entire category, and that has given us a solid foundation — I'll get into what that means later, both for future growth and opportunity in the broader Australian retail market and for how we think about overseas. Following a fairly strong Q3, Q3 in the wholesale space was somewhat elevated. Interest from wholesale has kept climbing in the pipeline we continue to build. What you see reflected in those numbers, though, is the timing of orders, in that gap tied to a smaller customer base when it comes to the cyclical timing of those big bulk orders. Now, looking at that third channel and talking about online, again, a real cornerstone for us is Australia — sorry, is it Amazon U.S.

Matthew Kowal

executive
#12

And Australia added close to $0.5 million. And based purely on what we've observed during the latest quarter — better logistics and fresh opportunities in that market — we anticipate this becoming yet another major area of focus for growth across all 3 channels. Turning now to how the various markets are performing. As we mentioned, Australia delivered a fantastic quarter, really powered by that retail growth. Once again, this shows what it means for the region, and for the overall business too, with 45% of sales for the entire business coming from retail. But also, it shows how we take that blueprint and that learning, not just to keep Australia growing, but where we can apply it overseas, which leads me to the United States, still very much the key growth market in our view. Consider the fact that it has contributed a strong 41% to total revenue. And that rests on e-commerce plus a wholesale business and customer base that we've built and that remain at quite an early stage. Given the blueprint I just described with Fiji Kava in Australia, we've taken those first steps into the U.S.

Matthew Kowal

executive
#13

On the retail development side, we've partnered with a seasoned retail broker who brings specific expertise with Kava and Kava brands. And we'll be aiming to put that fully into motion starting the next financial year or in this current FY '27. Fiji in the Pacific continues to be very important to us from a visibility standpoint, along with that storytelling and authenticity for our brands. And obviously, where we're situated from a factory perspective. And I think, reflecting on what Zane said, what would emerge from this financial year, if there are 3 distinct channels now. And if you look at revenue over the last 2 quarters, we've seen meaningful revenue in each of these channels. So now we have a strength for costs that will allow us to move into FY '27 with each of these carrying its own opportunities with significant growth. When you look at the 3 retail, again, led strongly by Australia, looking at that broader market access now when we talk about the piss or the basically vacant micro tablets as well as understanding how the category itself is growing from powders through to the flavored version and how that will cycle back into creating its own sort of funnel and growth and then how we replicate that.

Matthew Kowal

executive
#14

So, looking at this quarter, we've already signed up — we have the Coles success for the pavement tablet called FZZR, and we've also agreed to brokerage partners in both New Zealand and the U.S., which really gives us a strong platform for where retail is heading. Online continues to be a really important channel for us, both in terms of engagement and in volume and growth, especially while the other two are growing and looking to mature. What we're really focused on this quarter is driving those efficiencies and effectiveness, and that has underpinned the drop in overall spend while we try to maintain revenue and also the look back to Shopify in early Q1 FY '27, as they're being identified as places where we'll get better efficiencies and better effectiveness and conversions with our customers. Lastly, on the three channels, we're looking at wholesale — we're all very excited about what we've already created there, but also the amount of engagement we're getting in market and building on those pipelines. There's a lot of focus on building those long-conversation but long-life partnerships. We've seen revenue this quarter be significant, but down. And a lot of that is really just directly reflected by the cyclical orders that come with customers, which really just means our focus is on bringing in a broader range of customers and expanding that small but ongoing base.

Matthew Kowal

executive
#15

Let me spend a moment on the retail side. What we’re seeing in Australia, I think, is that recent jump, and it comes from finally getting in place the things we want for mainstream adoption — first with the powders we have, but also with the agreed ranging of the effervescent tablets. That creates not just a chance to sell the main powder product but almost a funnel that lets people come in and experience what Kava can do. Then, as we see across a lot of our product purchases, both online and in retail, they’ll usually go on to buy a bigger bulk powder. So it’s really widening the funnel opportunity we have in retail and letting the retailer do a key job for us — giving people the ability to become aware of us and trial us. Add to that steady improvements in our supply and really focusing on landing the right price. And that’s shown up over the last 12 months, when we’ve had 2 price rises in retail and still remain a leader in that stress category, because people see value in what Kava delivers against their needs.

Matthew Kowal

executive
#16

What matters most in the U.S. picture—and the reason this blueprint excites us, though we're also taking deliberate time on how we roll it out—is that major brands over there are beginning to enter that space. We mention Lay Lows, Kava Havens, plus another four or five names that already have retail penetration. So Kava is familiar now, and that gives us a chance to apply what we've learned and execute in those larger U.S. markets. The final piece to grasp before I hand things to Zane is the opportunity wholesale presents. As I noted, it was an early channel for us, and the products were early too. Our Kava extracts already account for a meaningful slice of revenue. That will keep growing, as will the margin value they contribute to the business. Our key alignments with businesses keep rising, and our other processes let us broaden that range and supply a range the market increasingly wants and demands. We're seeing both U.S.

Matthew Kowal

executive
#17

There's also greater interest overall in extract products, with Kava viewed as a product that's growing, whereas other categories like CBD and THC are running into difficulties regarding how they're handled and regulated, especially in the U.S. Zane, I'll hand things back to you.

Zane Yoshida

executive
#18

Thanks, Matt. Yeah, this is an exciting one. Let's talk about the U.S. opportunity. I suppose what we've identified as the main drivers for uptake of Kava rather than THC or CBD in the Q&A — I think that's really key. So better cash performance and spending discipline. Cash on hand stood at $633,000 at the end of June, $1.88 million, a rise of 15% quarter-on-quarter, with cash receipts inventory holding steady at $1.5 million, including prepaid inventory. Net operating cash flow fell 9% for the quarter. Again, I mentioned this on the opening slide: advertising and marketing spend right across the business dropped roughly 30% — 31% quarter-on-quarter. Staff costs for the quarter stayed stable. We did report a 5% reduction in staff costs last quarter, and a further 4% the quarter before that as well. And naturally, with the proposed arrangements out of Fiji, we ought to see extra savings over the months ahead on that front too. Thanks, Matt. The other one is really input cost recovery, and I can go through that with Matt and what it meant for decision-making at retail as we came into January — we saw, given the reliance on Fiji source material, mainly because we were selling Fiji Kava branded products across retail in Australia.

Zane Yoshida

executive
#19

When it comes to any rise in raw material costs coming out of Fiji — and naturally, because of the discussions we have to hold with retail partners like Coles and Woolworths — the price review procedure is handled by a committee. A great deal of supporting documentation is required from both the Fed government and suppliers before they can reach an agreement on raising prices, and we genuinely ask that we find, or arrive at, some middle ground in that negotiation too. That procedure usually takes around 5 months. So in fact we managed to reach agreement with both Coles and Woolworths, which let us raise retail prices midway through May, and afterward we also lifted prices across the direct-to-consumer channels to keep price parity in that respect. So the recovery was really tied to retail. We now have price increases from mid-May right across our channels to support stronger margins through direct-to-consumer as well as retail. And of course, we've managed to secure additional regional supply, as I communicated earlier. Thank you, Matt. So I suppose I always like to speak to how important the regulatory framework is that we operate within, particularly here in Australia, and the United States is our 2 key markets.

Zane Yoshida

executive
#20

Right now in Australia, there are two routes available for selling Kava. The first one runs through the commercial pilot trial, which has been running since December 2021 — under it, we can import Kava, and we do the processing in Fiji. It goes through border clearance and then falls under Food Standards Australia and New Zealand, standard 2.6.3, as a food. The difficulty with that food standard regulation is that we can only sell traditional formats — the ones we sell to Coles and Woolworths, which, as mentioned earlier, have performed extremely well and now hold the #1 and #3 positions, respectively, across all of Australia in the stress category. As most of you probably know, the difficulty with Kava is its very earthy, unique taste. Personally, I have no problem with how Kava tastes, since I've been drinking it for nearly 40 years. But for keen consumers here in Australia, in the United States and beyond, it is a very challenging taste. So the second route for bringing Kava into Australia is as a complementary medicine — which basically means it is regulated by the Therapeutic Goods Administration rather than by a food standard for Australia and New Zealand.

Zane Yoshida

executive
#21

The distinction here is that we have to — actually, let me explain the format piece. As a complementary medicine, the only formats you're permitted to sell are tablets, capsules, and tea bags. However, it has to deliver a standardized dose of Kava's active constituents, the Kavalectones. The TGA and the FDA both recommend a daily dose of roughly 240 milligrams of those active constituents each day. That figure is genuinely backed by clinical trial evidence gathered here in Australia — work done with the University of Melbourne, the University of Queensland, and the University of Western Sydney — looking at how safe and effective water extracts are for things like targeting generalized anxiety disorders, for example. And because those clinical trials succeeded, they landed on those recommended daily dose levels. So the route that let us get visits onto the market is the second pathway, the one I described as a complementary medicine — the format there is actually micro tablets. If you know Berocca, say, the way it appears on shelves at Coles or Chemist Warehouse, it's the same idea. Those Berocca tablets are in fact complementary medicines under TGA oversight. So it would carry a standardized dose of vitamin C, or whatever else Berocca includes in that formula.

Zane Yoshida

executive
#22

And when it comes to the FZZRs, we've standardised the dose for each stick pack or sachet so that it matches half of the recommended daily dose, in agreement with the TGA. That said, during our Q&A I'll give a small demonstration of how these look from a dissolved mobility standpoint — I won't be able to let all of you taste it, but I can definitely assure you that, judging by the feedback we've received so far, it's fantastic. Australia matters here because Australia belongs to the Pacific Island Forum Secretariat, or PIFS, which is headquartered in Suva, Fiji, yet speaks for every regional government across the South Pacific. Australia and New Zealand take part in it too, together with all the Pacific Island nations. So back in 2024, in Tonga, the Pacific heads of government made a commitment to a regional Kava development strategy. What that means is that expanding the processing and the ensuing export of Noble Kava cultivated throughout the Pacific Island countries will be harmonised. So at present we're working toward 1 shared standard for Noble Cava across the whole Pacific. Progress on that front is good, in that it acknowledges the commitment made by the Pacific heads of government to regionalise and standardise Kava via the Department of Foreign Affairs and Trade and stand Australia.

Zane Yoshida

executive
#23

They've now backed the creation of a technical committee to write standards for Kava mixed with water, plus some thought about extending that to extract formats. We sit on the Technical Committee, and our inaugural meeting took place in Sydney in April this year. It matters a great deal, in the sense that a quality framework is something we need. We need standards that are again recognized through possible expansion with existing regional quality standards, such as codex elemetarius, which has been in place now since 2017. And codex elementerius is the World Health Organization and the food and agricultural organization, with an overarching umbrella to ensure we work within a certain framework of recognizing what's Noble Kava, what's not Noble Kava, and some of the quality parameters exporters need to consider as it relates to foreign matter, as it relates to moisture content, ash content, so on and so forth. So it's very good that the Australian government is now getting behind this in that sense, to ensure we are working towards a standard recognizing the commitment by Pacific government. In the United States, Kava when mixed with water is recognized as a food.

Zane Yoshida

executive
#24

We observed that in November 2024, the state of Hawaii likewise shifted to a recognized Kava and mix with water under grass, which is generally recognized as safe — making it the first state in the United States to take this step. In May this year I was in the U.S. alongside our Chairman, James Dunkin, at the Natural Products Association Fly in day, with meetings in Washington, and during that period we also had the chance to present to the FDA regarding the progress with the quality frameworks that have been put in place right across the South Pacific and what The Calmer Co is doing to support that initiative, but also to lead that initiative in certain aspects. So again, the whole vertical integration, the whole supply chain, the quality control associated with that is very important given the ongoing work to bring Kava back to the forefront and recognition, not just in the Pacific, not just in the U.S.A., Canada or New Zealand, but internationally. The other regulation for Kava in the United States, or category, I should say, is as a dietary supplement. So when you mix Kava with flavors, when you mix Kava with other ingredients it then is regulated as a dietary supplement in the U.S.A.

Zane Yoshida

executive
#25

Sure, the FDA is looking at additional modernization efforts, especially given the work we currently have underway in Australia and the Pacific around harmonizing Kava and the standards we're aiming to establish. The FDA is one of the quad member countries involved with Codex elementaries, which includes Australia and New Zealand, Canada, and the U.S. So they definitely have both oversight and participation on that front in connection with the work we keep doing there. And it matters a great deal, as I've said before, that we build a solid foundation for scale. Considering the controversy Kava has faced historically, especially coming out of Germany, and considering how successfully it was adopted as a prescription medicine there over so many years and the ban that followed, which caused the carbon market in the South Pacific to collapse back in 2002 and left Kava tarnished as a result, the continuing effort to lobby governments on the basis of a robust quality framework that we have now put in place and keep putting in place across specific areas is rebuilding confidence in cargo's safety and efficacy and making sure we also have traceability for that ingredient as it goes into finished products and then into brands and onto shelves through various channels.

Zane Yoshida

executive
#26

On the international side, I mentioned codex, and that framework serves as the broad regulatory umbrella. From the PIFS — that's the Pacific Island Forum Secretariat — standpoint, they keep focusing on two things. The first is market access so Kava can reenter and borders can reopen in Europe and the United Kingdom. In addition, they keep working on what is called geographical indication, to make sure Kava is recognized as something unique to the South Pacific. That matters given its history and its cultural importance to Pacific Island countries too. And given the resurgence of interest and demand in the areas where we operate in the United States, particularly. Having that recognition matters — that Kava, or pipometisticum as it is known, is unique to the South Pacific — and protecting that. So it is similar to what campaign is, Champagne has provenance unique to champagne in France. So we are doing a similar thing. And of course, a more enabling regulatory environment across Australia, the U.S. and internationally opens up our distribution opportunities, right? So I know for a fact with Europe, for instance, the Pacific Island Forum Secretariat and the working group behind market access have now been able to submit something called a novel food application for the EU government to consider regarding reentry of Kava into the European Union.

Zane Yoshida

executive
#27

Moving to the next slide. Thanks, Matt. Our main priorities are really about continuing to develop the foundational elements—supply, manufacturing excellence, and innovation capability—that I discussed in detail under strategic pillar I, since that underpins the quality and consistency of our Kava as it goes into every channel where we generate revenue for The Calmer Co. So I talked about direct-to-consumer, including Amazon, and shifting back to Shopify as a platform and rebuilding the direct-to-consumer channel in-house at The Calmer Co; Amazon keeps contributing very strongly to the revenue-generating engine. The other one, of course, is retail—Matt mentioned the plans to expand, given the success we've had here with Coles in Australia as well as Woolworths in Australia, into the natural products channel potentially out of the U.S.A. And given the uptake of Kava there, it would be silly not to take a look at that. We've had brands Matt mentioned, such as Lalo, for instance, now the #1 selling can beverage format in the nonalcoholic category in Sprout supermarkets, U.S. wide, for example. Just yesterday, I saw on DevNet, who review beverages globally, there's another brand called Carvajal, who have a liquor style format in the 750-mil bottle that have been awarded for the second year running as the #1 alcohol alternatives in that entry.

Zane Yoshida

executive
#28

We're seeing a lot of strong momentum, and we think there's still room to move in the Australian market. The launch of the flavored Kava FZZR format shortly is encouraging, as it will complement the traditional drinking formats we have there, and the price increases in Q4 FY '26 across all our pillars certainly help accelerate CCO toward cash flow breakeven. There's a lot of work, but a lot more ongoing work for CCO as we take next steps with a lot of the change in strategic direction. Again, building revenue and managing risk along the supply chain, but also where we generate revenue in this business across all 3 pillars that I've spoken to. So in Q3 FY '26, you could see how wholesale has grown from a very small number in FY '25, for example, to now a meaningful contribution ongoing from a quarter-to-quarter perspective. It may have dropped off to 16% contribution or 18% contribution for the quarter. But again, as we continue to layer the cake, so to speak, we're building wholesale customers that Mac continues to work on, and we should see wholesale come to the forefront and overtake retail and direct-to-consumer, including Amazon.

Zane Yoshida

executive
#29

And with the net contribution margin that we're getting through wholesale, plus the reality that we carry no direct selling advertising costs — once again, that stays a core focus for CCO, especially given some of the choices we've made regarding the partnership out and the contract manufacturing partners we have both in Australia and in India, which keep building strength and capability to support wholesale expansion over the coming months. Thank you, Matt. So, as I mentioned, it's really about making sure we've got a strong diversified base, correct? Strong foundations for scale are what we need. And I think we've shown that through the progress in wholesale, but also through contributing to the quality framework and foundations we're putting in place, not only in Fiji but right across the Pacific. That matters to ensure the carve being exported out of the Pacific is of the highest quality and to ensure we have traceability and transparency around it to support what we see as very strong demand. Certainly, from a CAGR compound annual growth rate perspective, carve is estimated to be growing at 14% to 16% per annum all the way through until 2033. And that figure has now shifted from the $5.6 billion in 2023 that we reported previously to around $7 billion now.

Zane Yoshida

executive
#30

It's an exciting time, yet we have to make sure there's a sustainable platform we can draw on to serve rising demand throughout the business. I mentioned that retail's contribution this quarter is very strong—it would have been stronger still had we raised retail prices earlier in the quarter—but we're certainly eager to see what Q1 FY '27 holds. That's certain, Matt. Cash management and customer receipts also rose this quarter. More importantly, we managed to hit these figures while cutting marketing and advertising costs by 31% for the quarter. So yes. Thanks, Matt.

Zane Yoshida

executive
#31

Let's go ahead and open it up to questions. I believe there aren't too many today—maybe you want to take a quick look. But I think we should discuss where the market stands, as heard from <<inaudible>>. What is fueling the growth in Kava demand, and what are we observing? Then let's cover what comes next in Australia regarding FZZRs, for instance, correct? And as I mentioned, I'll give a brief demonstration. So here is what the FZZRs are going to look like.

Matthew Kowal

executive
#32

You've got a couple in your mouths too, since it's a nice unique <<inaudible>>.

Zane Yoshida

executive
#33

Of course. So you can chew these — that's what they look like, small micro tablets. You can chew them. <<inaudible>>, but this as well. So that <<inaudible>>, and a lot — you'll have a flavored Kava beverage format that we'll be offering in the Australian market. So that's a really exciting step, working alongside Ryan Gorman and IMCD, of course, on this project. So the U.S.A., Matt, was just appointed to serve as our broker to grow retail presence beyond the U.S.A. I suppose what I'm seeing, from the discussions we keep having with interest around the table, is the farm build, for example, where they've managed to build a very strong category with CBD and THC formats. And many brands have hopped onto that bandwagon and performed really well. However, the constraint looming ahead for many of these brands is this. The farm bill will likely be reviewed unfavorably in November. And that's pushing a lot of these companies to look at alternative ingredients. And what else can you put in a beverage where, when you drink it, you feel it and you feel it almost right away.

Zane Yoshida

executive
#34

That's Kava. You consume it, and you experience the effect. So a great many formulators are coming forward. Plenty of firms these days are eyeing Kava ahead of its forbid review, for inclusion in those beverage formats — established brands holding meaningful US market share within the non-ALP category. They're now knocking at the door, weighing how to reformulate using Kava as the central ingredient. That, to me, is thrilling. Beyond what we discussed regarding Gen Zs, and beyond what we've covered, considering the therapeutic advantages we're aware of with Kava and what's fueling that growth for CCO. So what additional things are you observing there alongside all of this?

Matthew Kowal

executive
#35

Certainly. I believe there are a few ways regulatory shifts are pushing things. You can also point to areas where the right kinds of pressure are starting to show up too. So the market has several layers to it. And in fact, retailers want something that fills a gap where they've already had success with CBD or THC products. Then you have brands trying to offer new alternatives that aren't simple one-for-one substitutions. And then there are the manufacturers and the extractors, who are saying, well, we need other ingredients. There's this entire infrastructure built around farms and CBD processing that now potentially — will they face a market that isn't fully grinding to a halt but is heavily restricted, or a completely patented route to market, and what does that mean for CBD? So all at once everyone is asking, what alternative can fill that role? And I believe Kava is well positioned for all of those sets of motions. And it just so happens that this is a moment when Kava is already naturally on an upswing as well — really, I suppose, the market leaders, the first market, the Lalo, the cover havens, the Kava you talk on the allows products that have identified Kava and how it can be used.

Matthew Kowal

executive
#36

And I think what you're really seeing in the market, probably the biggest thing, is the shift into non-op or the calming drink, ready-to-drinks, whether that's large-format spirits or small RTDs, but edibles too. Again, that's a space where CBD played a really strong part — everyone's looking at different types of gummies to bring into that space as well. And the stick packs, a little bit like what we're doing with micro tablets here in Australia, but 1 in the U.S., where they're not restricted by the tablet format. There are a lot of powder-based pieces. So on the back of the culture of carrying a water bottle, when you're having it in the morning, evening, all those kind of things, even to — I think recently on the retail trip it was really interesting that most retailers had a stick pack area on the way out of store. So that's where they take it out of the box and they're putting it into where you normally get your thing and those kind of elements, and people going impulse buy and out the door, whether it's from vitamins, hydration to functionals where Kava's now setting. So — and the way we set the business up, we want to be able to try peak out of all of that.

Matthew Kowal

executive
#37

We aim to seize what the retail side offers, though in the proper manner—a smart manner. We want to ensure we're supplying everyone we possibly can via wholesale. And then there's the general growth you inevitably observe in categories and markets that begin to mature in retail—everything expands since there's wider comprehension of it. There's wider involvement with it. So look, genuinely strenuous effort was needed to reach this point now, to prepare for the coming year, to have those 3 channels in place now, but we're at a stage where we'll push aggressively and, in a sense, grasp the opportunity present in a market that's expanding across numerous locations.

Zane Yoshida

executive
#38

Right, absolutely. And there are still restrictions on where THC and CBD products can be sold. Take Amazon, for instance — you can't sell them there, correct, while Kava is something you can sell, right? So a massive opportunity sits right there with the biggest e-commerce platform on the planet, ready to be capitalized on through that expansion and those upcoming steps.

Matthew Kowal

executive
#39

Yes. Exactly. And I think it's similar but in a different way in Australia, clearly, given what we're doing there with the pies and the microtablets, along with the TGA and the flavored process. We've had to operate inside that framework. But what that accomplishes, again, is it creates a wider opportunity for people who might be reluctant to make the leap into that 50 grams of Kava at powder with a very distinct taste. A good way here is to come in, try it, develop a sense of how it suits them. And then, as we've observed repeatedly, among people who give trial Kava a go, a large percentage return, since it truly is a functional ingredient — you have it, you feel it.

Zane Yoshida

executive
#40

Correct, exactly. That's correct. You never actually sense that vitamin C capsule or tablet you take each morning, do you?

Matthew Kowal

executive
#41

Sure thing.

Zane Yoshida

executive
#42

Absolutely.

Matthew Kowal

executive
#43

Still releases <<inaudible>>.

Zane Yoshida

executive
#44

I'm keeping an eye on the clock here, and we've already hit the hour mark. Perhaps I've gone on a bit long, Matt. That said, is there anything further we should address today that would serve investors and benefit shareholders? Please go ahead.

Matthew Kowal

executive
#45

Yes. Probably I'd simply emphasize — I think what's emerging in a few of the announcements is that we're very focused on growing the business at both ends, making sure supply share excellence is in place. And then I think it's just about communicating where we stand at each of those stages across the channels, which we've actually walked everyone through clearly today. And please feel free to keep sending those questions in even afterward, and we can answer them. But we have an opportunity, and we've already begun what is a genuinely exciting journey in wholesale, and we've only got more to bring to that. And in talking to the market, we know we hold strengths that others don't. We have a fantastic setup in retail in Australia that's exciting to expand further. And then, as I said, our online business, which has been strong, has only more excitement ahead, I think, with some key changes involving Shopify and bringing that handling back in-house so we can be quite aggressive in how we take that to market.

Zane Yoshida

executive
#46

Yes. Alright. Given the Q3 FY '26 results, I believe we've addressed the unevenness in wholesale and how that affected the quarter, though naturally we aim to smooth that out and take the wholesale channel further with our next move. So keep an eye out, as the saying goes. Thanks, Matt. That brings our Q4 FY '26 webinar to a close. Thank you to everyone who took part.

Matthew Kowal

executive
#47

I appreciate that.

Zane Yoshida

executive
#48

That’s all from me.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete The Calmer Co International Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to The Calmer Co International Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in The Calmer Co International Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.